Publications by authors named "Amy Wohltman"

Claim this Profile

Mentions over time

Mentions by platform

Video Views

186

Total Likes

337

Extended Reach

4,392,587

Social Features

131
E
Effect of Aficamten Compared With Metoprolol on Echocardiographic Measures in Symptomatic Obstructive Hypertrophic Cardiomyopathy: MAPLE-HCM.
Sheila M Hegde, Xiaowen Wang, Pablo Garcia-Pavia, Stoyan Getchevski, Ahmad Masri, Amy Wohltman

J Am Coll Cardiol· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effect of Aficamten in Women Compared with Men with Obstructive Hypertrophic Cardiomyopathy in SEQUOIA-HCM.
Xiaowen Wang, Maria A Pabon, Tracy T Makuvire, Reziwanguli Maimaiti, Theodore P Abraham, Amy Wohltman

Circ Heart Fail· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Aficamten in Obstructive Hypertrophic Cardiomyopathy: A Multidomain, Patient-Level Analysis of the MAPLE-HCM Trial.
Andrew Wang, Pablo Garcia-Pavia, Ahmad Masri, Bela Merkely, Michael E Nassif, Amy Wohltman

J Am Coll Cardiol· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effect of Aficamten vs Metoprolol on Patient-Reported Health Status in Obstructive Hypertrophic Cardiomyopathy.
Michael E Nassif, Pablo Garcia-Pavia, Ahmad Masri, Bela Merkely, Maria Luisa Peña-Peña, Amy Wohltman

J Am Coll Cardiol· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Characterization and Application of Novel Exercise Recovery Patterns That Reflect Cardiac Performance: A Substudy of the SEQUOIA-HCM Trial.
Joseph Campain, Catharine Griskowitz, Chloe Newlands, Brian L Claggett, Ian J Kulac, Amy Wohltman

Circulation· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy of aficamten in patients with obstructive hypertrophic cardiomyopathy and mild symptoms: results from the SEQUOIA-HCM trial.
Martin S Maron, Juan Ramon Gimeno, Josef Veselka, Roberto Barriales-Villa, Brian L Claggett, Amy Wohltman

Eur Heart J· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Aficamten or Metoprolol Monotherapy for Obstructive Hypertrophic Cardiomyopathy.
Pablo Garcia-Pavia, Martin S Maron, Ahmad Masri, Bela Merkely, Michael E Nassif, Amy Wohltman

N Engl J Med· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Aficamten vs Metoprolol for Obstructive Hypertrophic Cardiomyopathy: MAPLE-HCM Rationale, Study Design, and Baseline Characteristics.
Pablo Garcia-Pavia, Ozlem Bilen, Melissa Burroughs, Juan Pablo Costabel, Edileide de Barros Correia, Amy Wohltman

JACC Heart Fail· February 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy and Safety of Aficamten in Symptomatic Nonobstructive Hypertrophic Cardiomyopathy: Results From the REDWOOD-HCM Trial, Cohort 4.
Ahmad Masri, Mark V Sherrid, Theodore P Abraham, Lubna Choudhury, Pablo Garcia-Pavia, Amy Wohltman

J Card Fail· November 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cardiac biomarkers and effects of aficamten in obstructive hypertrophic cardiomyopathy: the SEQUOIA-HCM trial.
Caroline J Coats, Ahmad Masri, Roberto Barriales-Villa, Theodore P Abraham, Douglas Marshall Brinkley, Amy Wohltman

Eur Heart J· November 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Impact of Aficamten on Echocardiographic Cardiac Structure and Function in Symptomatic Obstructive Hypertrophic Cardiomyopathy.
Sheila M Hegde, Brian L Claggett, Xiaowen Wang, Karola Jering, Narayana Prasad, Amy Wohltman

J Am Coll Cardiol· November 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effect of Aficamten on Cardiac Structure and Function in Obstructive Hypertrophic Cardiomyopathy: SEQUOIA-HCM CMR Substudy.
Ahmad Masri, Rhanderson N Cardoso, Theodore P Abraham, Brian L Claggett, Caroline J Coats, Amy Wohltman

J Am Coll Cardiol· November 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effect of Aficamten on Health Status Outcomes in Obstructive Hypertrophic Cardiomyopathy: Results From SEQUOIA-HCM.
Charles F Sherrod, Sara Saberi, Michael E Nassif, Brian L Claggett, Caroline J Coats, Amy Wohltman

J Am Coll Cardiol· November 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Aficamten and Cardiopulmonary Exercise Test Performance: A Substudy of the SEQUOIA-HCM Randomized Clinical Trial.
Matthew M Y Lee, Ahmad Masri, Michael E Nassif, Roberto Barriales-Villa, Theodore P Abraham, Amy Wohltman

JAMA Cardiol· November 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Impact of Aficamten on Disease and Symptom Burden in Obstructive Hypertrophic Cardiomyopathy: Results From SEQUOIA-HCM.
Martin S Maron, Ahmad Masri, Michael E Nassif, Roberto Barriales-Villa, Theodore P Abraham, Amy Wohltman

J Am Coll Cardiol· November 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Dosing and Safety Profile of Aficamten in Symptomatic Obstructive Hypertrophic Cardiomyopathy: Results From SEQUOIA-HCM.
Caroline J Coats, Ahmad Masri, Michael E Nassif, Roberto Barriales-Villa, Michael Arad, Amy Wohltman

J Am Heart Assoc· August 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Exercise Capacity in Patients With Obstructive Hypertrophic Cardiomyopathy: SEQUOIA-HCM Baseline Characteristics and Study Design.
Caroline J Coats, Martin S Maron, Theodore P Abraham, Iacopo Olivotto, Matthew M Y Lee, Amy Wohltman

JACC Heart Fail· January 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Aficamten for Drug-Refractory Severe Obstructive Hypertrophic Cardiomyopathy in Patients Receiving Disopyramide: REDWOOD-HCM Cohort 3.
Anjali T Owens, Ahmad Masri, Theodore P Abraham, Lubna Choudhury, Florian Rader, Amy Wohltman

J Card Fail· November 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase 2 Study of Aficamten in Patients With Obstructive Hypertrophic Cardiomyopathy.
Martin S Maron, Ahmad Masri, Lubna Choudhury, Iacopo Olivotto, Sara Saberi, Amy Wohltman

J Am Coll Cardiol· January 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effect of Omecamtiv Mecarbil on Exercise Capacity in Chronic Heart Failure With Reduced Ejection Fraction: The METEORIC-HF Randomized Clinical Trial.
Gregory D Lewis, Adriaan A Voors, Alain Cohen-Solal, Marco Metra, David J Whellan, Amy Wohltman

JAMA· July 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis